TRUMF - Terumo Corporation (TRUMF) CEO Shinjiro Sato on Q4 2021 Results - Earnings Call Transcript

Terumo Corporation (TRUMF) Q4 2021 Results Conference Call May 13, 2021 10:00 AM ET Company Participants Shinjiro Sato - President and CEO Naoki Muto - CFO Conference Call Participants Presentation Naoki Muto I am the CFO, Muto. I will now explain the results for the fiscal year ended March 2021. First, here is a summary of highlights of the results. Sales revenue for the year saw steady recovery, thanks to the return of demand despite remaining effects of COVID-19 in the second half on the Cardiac and Vascular Company. In the General Hospital and Blood and Cell Technologies companies, products related to infection prevention and COVID-19 treatment contributed to increased sales revenue and to stability for the group as a whole. Although some impact remained, the most recent stand-alone fourth quarter results showed our highest ever Q4 sales revenue. In adjusted operating profit, there was some negative gross profit impact

For further details see:

Terumo Corporation (TRUMF) CEO Shinjiro Sato on Q4 2021 Results - Earnings Call Transcript